News

FDA Grants Rare Pediatric Disease Designation to Anavex 2-73 for Rett Syndrome

The U.S. Food and Drug Administration (FDA) has granted rare pediatric disease designation to Anavex 2-73 (blarcamesine) for the treatment of Rett syndrome. This designation provides priority review to investigational treatments that have the potential to provide clinically meaningful benefits in serious rare diseases mainly affecting individuals younger than 18. If…

Newron Seeks Participants for Global Survey on Burden of Rett

In partnership with the Rett syndrome community, Newron Pharmaceuticals has launched a groundbreaking International Rett Syndrome Burden of Illness Survey. The first of its kind, the study will examine the physical, emotional, and financial impact of Rett syndrome on patients, families, and caregivers. Its findings are expected…